Wei-Wu He - 23 Mar 2026 SCHEDULE 13D/A Report for CASI Pharmaceuticals, Inc. Ordinary Shares (CASIF)

Filing Manager
Wei-Wu He
Reporting Manager
WEI-WU HE, Ph.D.
Security
CASI Pharmaceuticals, Inc. Ordinary Shares
Symbol
CASIF
Shares outstanding
35,821,764 shares
Disclosed Ownership
18,985,535 shares
Ownership
53%
Form type
SCHEDULE 13D/A
Filing time
23 Mar 2026, 06:40:36 UTC
Date of event
23 Mar 2026
Previous filing
10 Feb 2026
SEC
View on sec.gov

Quoteable Key Fact

"Wei-Wu He disclosed 53% ownership in CASI Pharmaceuticals, Inc. Ordinary Shares (CASIF) on 23 Mar 2026."

Quick Takeaways

  • Wei-Wu He filed SCHEDULE 13D/A for CASI Pharmaceuticals, Inc. Ordinary Shares (CASIF).
  • Disclosed ownership: 53%.
  • Date of event: 23 Mar 2026.

What Changed

  • Previous schedule filing date: 10 Feb 2026.
  • Current filing was accepted on 23 Mar 2026, 06:40.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Source Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (7)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
WEI-WU HE, Ph.D. 53% 18,985,535 2,150,550 16,834,985 /s/ Wei-Wu He, Ph.D. Wei-Wu He, Ph.D. 0001542073
HUIYING MEMORIAL FOUNDATION 3.1% 637,644 0 637,644 /s/ Wei-Wu He, Ph.D. Wei-Wu He, Ph.D./President
EMERGING TECHNOLOGY PARTNERS, LLC 45% 16,097,341 0 16,097,341 /s/ Wei-Wu He, Ph.D. Wei-Wu He, Ph.D./ Managing Member
ETP Global Fund L.P. 3.7% 753,234 0 753,234 EMERGING TECHNOLOGY PARTNERS, LLC General Partner
ETP BIOHEALTH III FUND, L.P. 1.5% 300,000 0 300,000 EMERGING TECHNOLOGY PARTNERS, LLC General Partner
HE Family GRAT 0.5% 100,000 0 100,000 /s/ Wei-Wu He, Ph.D. Wei-Wu He, Ph.D./Trustee
ETP Global III Fund L.P. 42% 15,000,000 0 15,000,000 EMERGING TECHNOLOGY PARTNERS, LLC General Partner
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .